Index -
P/E -
EPS (ttm) -1.56
Insider Own 45.15%
Shs Outstand 5.37M
Perf Week 0.61%
Market Cap 8.86M
Forward P/E -
EPS next Y -3.93
Insider Trans 11.50%
Shs Float 2.95M
Perf Month -13.16%
Income -8.12M
PEG -
EPS next Q -0.78
Inst Own 50.57%
Short Float 6.97%
Perf Quarter -52.99%
Sales 57.31M
P/S 0.15
EPS this Y -80.56%
Inst Trans -24.26%
Short Ratio 3.13
Perf Half Y -72.50%
Book/sh 0.78
P/B 2.11
EPS next Y -20.92%
ROA -12.22%
Short Interest 0.21M
Perf Year -72.00%
Cash/sh 2.15
P/C 0.77
EPS next 5Y 3.20%
ROE -478.86%
52W Range 1.40 - 9.45
Perf YTD -55.76%
Dividend Est. -
P/FCF -
EPS past 5Y 34.83%
ROI -58.22%
52W High -82.54%
Beta 1.15
Dividend TTM -
Quick Ratio 0.97
Sales past 5Y 59.75%
Gross Margin 88.17%
52W Low 17.86%
ATR (14) 0.20
Dividend Ex-Date -
Current Ratio 0.97
EPS Y/Y TTM 93.70%
Oper. Margin -18.26%
RSI (14) 38.74
Volatility 10.16% 10.03%
Employees 62
Debt/Eq 2.90
Sales Y/Y TTM 190.10%
Profit Margin -14.18%
Recom 1.00
Target Price 18.00
Option/Short No / Yes
LT Debt/Eq 2.31
EPS Q/Q 87.48%
Payout -
Rel Volume 0.66
Prev Close 1.66
Sales Surprise -9.76%
EPS Surprise 24.74%
Sales Q/Q 168.71%
Earnings Mar 29 BMO
Avg Volume 65.70K
Price 1.65
SMA20 -4.15%
SMA50 -33.83%
SMA200 -67.43%
Trades
Volume 43,645
Change -0.60%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-21-21 Initiated
BofA Securities
Buy
$12
Feb-01-21 Initiated
UBS
Neutral
$13
Sep-08-20 Initiated
Jefferies
Buy
$21
Mar-25-20 Initiated
Stifel
Buy
$19
Feb-27-20 Initiated
Barclays
Overweight
$22
Apr-29-19 Initiated
UBS
Buy
$12
Dec-11-18 Initiated
Oppenheimer
Outperform
$15
Oct-08-18 Initiated
Laidlaw
Buy
$18
Apr-11-24 01:52PM
Apr-09-24 08:11AM
Mar-29-24 08:21AM
Mar-28-24 08:11AM
Mar-04-24 08:11AM
05:55PM
Loading…
Feb-08-24 05:55PM
Nov-13-23 04:11PM
Nov-02-23 04:11PM
Nov-01-23 04:12PM
Sep-28-23 04:11PM
Aug-25-23 08:50AM
Aug-11-23 11:22AM
Aug-10-23 08:08AM
Aug-04-23 09:16AM
(American City Business Journals)
Aug-02-23 04:11PM
06:55AM
Loading…
Jul-20-23 06:55AM
Jul-13-23 08:14AM
Jun-16-23 08:56PM
Jun-01-23 07:57AM
May-26-23 05:10PM
May-15-23 04:13PM
May-04-23 10:00AM
Apr-17-23 08:00AM
Apr-07-23 06:50PM
Mar-30-23 07:25PM
06:10PM
Mar-09-23 10:02AM
Mar-01-23 04:44PM
Dec-02-22 05:02PM
Nov-23-22 04:30PM
07:39AM
Loading…
Nov-13-22 07:39AM
Nov-10-22 05:55PM
04:15PM
Nov-04-22 11:00AM
Aug-31-22 04:52PM
Aug-17-22 06:17AM
Aug-11-22 04:10PM
Aug-08-22 10:00AM
Aug-04-22 10:00AM
Jun-06-22 08:00AM
May-17-22 04:05PM
May-12-22 04:30PM
May-10-22 05:25PM
May-06-22 10:18AM
May-05-22 05:55PM
03:00PM
May-04-22 07:25AM
Apr-12-22 07:30AM
Apr-08-22 08:00AM
Mar-28-22 04:30PM
Mar-18-22 12:39PM
Mar-02-22 08:00AM
Mar-01-22 08:00AM
Jan-17-22 07:08AM
Nov-30-21 05:30PM
Nov-18-21 08:00AM
Nov-16-21 09:06AM
Nov-15-21 12:25PM
07:30AM
Oct-28-21 03:05PM
12:31PM
Oct-12-21 09:08AM
Sep-22-21 03:24AM
Sep-20-21 08:00AM
Sep-14-21 12:09PM
Aug-12-21 08:05PM
04:30PM
Aug-05-21 10:50AM
Jul-29-21 03:05PM
Jul-21-21 03:20PM
Jul-19-21 05:27AM
Jul-09-21 08:00AM
Jul-06-21 08:00AM
Jun-30-21 08:30AM
May-18-21 03:04AM
May-13-21 07:50PM
04:30PM
Apr-20-21 11:36AM
Apr-12-21 07:00AM
Apr-05-21 04:12PM
11:48AM
07:00AM
Mar-21-21 03:37AM
Mar-18-21 04:30PM
Feb-26-21 08:00AM
Feb-21-21 03:02AM
Feb-18-21 07:30AM
Feb-17-21 04:05PM
Feb-11-21 09:13AM
07:30AM
Feb-08-21 06:20AM
Jan-19-21 08:00AM
Dec-21-20 04:30PM
Dec-18-20 10:21PM
Nov-30-20 09:54PM
Nov-28-20 11:30PM
Nov-25-20 10:10PM
Nov-23-20 11:15PM
Nov-21-20 11:23PM
Nov-18-20 10:00PM
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariepy, and Leigh Revers in 2001 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIOTECH TARGET N V 10% Owner Apr 02 '24 Buy 2.35 250,000 587,500 1,279,820 Apr 04 08:13 PM BIOTECH TARGET N V 10% Owner Jul 17 '23 Buy 0.47 4,255,319 2,000,000 15,447,322 Jul 19 03:14 PM
Index RUT
P/E -
EPS (ttm) -0.15
Insider Own 6.45%
Shs Outstand 62.07M
Perf Week -0.96%
Market Cap 972.81M
Forward P/E -
EPS next Y -1.65
Insider Trans -6.78%
Shs Float 58.52M
Perf Month 16.83%
Income -9.06M
PEG -
EPS next Q -0.64
Inst Own 94.83%
Short Float 14.69%
Perf Quarter 8.74%
Sales 58.75M
P/S 16.56
EPS this Y -1616.78%
Inst Trans -8.39%
Short Ratio 5.61
Perf Half Y 201.36%
Book/sh 2.46
P/B 6.32
EPS next Y 36.03%
ROA -3.04%
Short Interest 8.60M
Perf Year 109.85%
Cash/sh 3.67
P/C 4.23
EPS next 5Y -
ROE -6.15%
52W Range 4.29 - 21.88
Perf YTD 61.64%
Dividend Est. -
P/FCF -
EPS past 5Y 48.88%
ROI -4.95%
52W High -28.93%
Beta 2.08
Dividend TTM -
Quick Ratio 4.46
Sales past 5Y 15.77%
Gross Margin 69.59%
52W Low 262.47%
ATR (14) 1.12
Dividend Ex-Date -
Current Ratio 4.48
EPS Y/Y TTM 92.56%
Oper. Margin -286.38%
RSI (14) 47.62
Volatility 7.46% 7.42%
Employees 339
Debt/Eq 0.22
Sales Y/Y TTM -61.33%
Profit Margin -15.42%
Recom 1.25
Target Price 24.80
Option/Short Yes / Yes
LT Debt/Eq 0.20
EPS Q/Q -457.69%
Payout -
Rel Volume 0.62
Prev Close 14.78
Sales Surprise -67.15%
EPS Surprise -382.08%
Sales Q/Q -85.33%
Earnings Mar 07 AMC
Avg Volume 1.53M
Price 15.55
SMA20 -5.10%
SMA50 -6.48%
SMA200 57.04%
Trades
Volume 957,323
Change 5.21%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-26-24 Initiated
B. Riley Securities
Buy
$25
Apr-09-24 Upgrade
TD Cowen
Hold → Buy
Mar-04-24 Reiterated
BTIG Research
Buy
$12 → $24
Feb-14-24 Downgrade
H.C. Wainwright
Buy → Neutral
$12 → $14
Dec-20-23 Upgrade
Citigroup
Neutral → Buy
$7 → $13
Nov-07-23 Upgrade
Guggenheim
Neutral → Buy
$12
Mar-17-23 Downgrade
Guggenheim
Buy → Neutral
Nov-22-22 Downgrade
Cowen
Outperform → Market Perform
Nov-14-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$5.70 → $16
Jul-18-22 Downgrade
SMBC Nikko
Outperform → Neutral
$5
Jul-11-22 Downgrade
BMO Capital Markets
Outperform → Market Perform
$31 → $4
May-04-22 Downgrade
Guggenheim
Buy → Neutral
Feb-28-22 Upgrade
Citigroup
Neutral → Buy
$23 → $21
Feb-11-22 Initiated
BMO Capital Markets
Outperform
$31
Feb-04-22 Initiated
SMBC Nikko
Outperform
$40
Nov-17-21 Resumed
Guggenheim
Buy
$30
Oct-19-21 Initiated
JMP Securities
Mkt Outperform
$39
Oct-15-21 Resumed
BTIG Research
Buy
$50
Apr-26-21 Resumed
Credit Suisse
Outperform
$37
Mar-12-21 Upgrade
Barclays
Underweight → Overweight
$14 → $40
Show Previous Ratings
Today 10:05AM
Apr-26-24 08:00AM
Apr-03-24 04:30PM
Mar-14-24 08:18AM
Mar-09-24 01:09PM
07:19AM
Loading…
Mar-08-24 07:19AM
(Thomson Reuters StreetEvents) -15.02%
12:30AM
Mar-07-24 10:42PM
09:55PM
05:30PM
04:01PM
Mar-06-24 11:29PM
Mar-01-24 05:48PM
Feb-29-24 10:00AM
Feb-27-24 05:45PM
04:30PM
Loading…
Feb-02-24 04:30PM
07:19AM
Jan-15-24 04:51PM
Jan-08-24 04:30PM
Dec-17-23 12:03PM
Nov-07-23 10:56AM
(Thomson Reuters StreetEvents) +17.10%
08:59AM
01:15AM
Nov-06-23 05:12PM
04:27PM
(Associated Press Finance)
04:01PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Sep-05-23 07:00AM
Aug-31-23 04:30PM
07:40AM
Loading…
Aug-19-23 07:40AM
Aug-14-23 11:19AM
Aug-11-23 01:26PM
Aug-10-23 12:33PM
07:01AM
(Thomson Reuters StreetEvents)
Aug-09-23 11:30PM
05:50PM
04:52PM
04:01PM
Jul-31-23 05:35PM
Jul-05-23 11:55AM
Jun-28-23 08:12AM
Jun-08-23 07:27AM
May-14-23 08:09AM
May-10-23 12:10PM
12:30AM
May-09-23 05:25PM
04:21PM
04:01PM
May-05-23 08:27AM
May-04-23 04:30PM
Apr-25-23 10:01AM
Apr-24-23 06:15PM
Apr-07-23 08:48AM
Mar-22-23 01:22PM
Mar-20-23 06:59PM
Mar-18-23 02:52AM
Mar-17-23 06:15PM
Mar-16-23 12:17PM
07:10AM
(Thomson Reuters StreetEvents)
Mar-15-23 11:00PM
05:35PM
04:01PM
Mar-14-23 12:32PM
08:00AM
Mar-11-23 07:30AM
Mar-09-23 03:59PM
Mar-08-23 05:36PM
Mar-07-23 06:00PM
Mar-02-23 04:30PM
Feb-20-23 09:56AM
Feb-17-23 06:27AM
Feb-14-23 10:01AM
Feb-13-23 05:20PM
Feb-06-23 04:30PM
Jan-24-23 07:57AM
06:48AM
Jan-06-23 06:15PM
Jan-04-23 05:50PM
04:30PM
Jan-02-23 09:57AM
Dec-29-22 06:51AM
Dec-06-22 08:01AM
04:48AM
Dec-05-22 09:55AM
Dec-02-22 09:35AM
Nov-29-22 12:57PM
Nov-22-22 11:55AM
Nov-18-22 02:54PM
(American City Business Journals)
10:15AM
08:39AM
Nov-17-22 06:10PM
09:55AM
Nov-14-22 06:31PM
Nov-09-22 05:31AM
Nov-07-22 06:40PM
03:02PM
(American City Business Journals)
Nov-04-22 06:51PM
Nov-03-22 11:30PM
06:05PM
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Peters Jeffrey Stuart Senior VP and General Counsel Apr 04 '24 Option Exercise 4.82 42,500 204,850 51,395 Apr 08 06:07 PM Peters Jeffrey Stuart Senior VP and General Counsel Apr 04 '24 Sale 15.55 51,395 799,148 0 Apr 08 06:07 PM Peters Jeffrey Stuart Senior VP and General Counsel Mar 06 '24 Option Exercise 10.90 19,625 213,875 28,520 Mar 08 04:14 PM Peters Jeffrey Stuart Senior VP and General Counsel Mar 06 '24 Sale 21.50 19,625 421,938 8,895 Mar 08 04:14 PM Risser Eric Blasius Chief Operating Officer Mar 04 '24 Option Exercise 10.15 15,000 152,250 80,059 Mar 06 04:20 PM Spitznagel Thomas Sr VP, Technical Ops Mar 04 '24 Option Exercise 11.50 10,000 115,000 18,316 Mar 06 04:19 PM Risser Eric Blasius Chief Operating Officer Mar 04 '24 Sale 19.76 41,159 813,501 38,900 Mar 06 04:20 PM Karrels James SVP, CFO and Secretary Mar 04 '24 Sale 20.50 30,000 615,000 171,452 Mar 06 04:18 PM Spitznagel Thomas Sr VP, Technical Ops Mar 04 '24 Sale 20.00 10,000 200,000 8,316 Mar 06 04:19 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 26 '24 Sale 17.22 16,124 277,655 8,895 Feb 28 04:20 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 22 '24 Option Exercise 0.00 26,250 0 35,145 Feb 26 04:27 PM Bonvini Ezio Sr VP, Research & CSO Feb 22 '24 Option Exercise 0.00 28,125 0 110,258 Feb 26 04:26 PM Bonvini Ezio Sr VP, Research & CSO Feb 15 '24 Option Exercise 0.00 16,670 0 88,004 Feb 20 06:03 PM Risser Eric Blasius Chief Operating Officer Feb 15 '24 Option Exercise 0.00 16,670 0 70,938 Feb 20 06:04 PM Cilinski Lynn VP, Controller and Treasurer Feb 15 '24 Option Exercise 0.00 6,668 0 8,591 Feb 20 06:04 PM Koenig Scott President and CEO Feb 15 '24 Option Exercise 0.00 42,341 0 1,091,977 Feb 20 06:04 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 15 '24 Option Exercise 0.00 13,336 0 13,336 Feb 20 06:05 PM Spitznagel Thomas Sr VP, Technical Ops Feb 15 '24 Option Exercise 0.00 13,336 0 13,336 Feb 20 06:03 PM Karrels James SVP, CFO and Secretary Feb 15 '24 Option Exercise 0.00 15,003 0 206,779 Feb 20 06:04 PM Eck Stephen L. Chief Medical Officer Feb 15 '24 Option Exercise 0.00 16,670 0 16,670 Feb 20 06:41 PM Bonvini Ezio Sr VP, Research & CSO Feb 07 '24 Sale 18.00 3,334 60,012 71,334 Feb 07 04:19 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 05 '24 Option Exercise 11.11 76,251 847,355 76,251 Feb 07 04:17 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 05 '24 Sale 16.50 76,251 1,258,142 0 Feb 07 04:17 PM Bonvini Ezio Sr VP, Research & CSO Feb 01 '24 Sale 15.00 13,316 199,740 74,668 Feb 02 04:21 PM Bonvini Ezio Sr VP, Research & CSO Jan 19 '24 Sale 12.00 13,316 159,792 87,984 Jan 22 04:57 PM Bonvini Ezio Sr VP, Research & CSO Dec 20 '23 Sale 10.08 18,880 190,310 101,300 Dec 21 04:12 PM BIOTECH TARGET N V 10% Owner Oct 02 '23 Buy 4.46 150,000 669,585 9,929,963 Oct 04 03:31 PM BIOTECH TARGET N V 10% Owner Sep 07 '23 Buy 5.26 200,000 1,052,840 9,779,963 Sep 11 03:39 PM HURWITZ EDWARD Director Aug 30 '23 Buy 4.91 15,000 73,650 33,074 Sep 01 04:06 PM
Index RUT
P/E -
EPS (ttm) -2.28
Insider Own 8.63%
Shs Outstand 27.31M
Perf Week -3.35%
Market Cap 484.33M
Forward P/E 20.13
EPS next Y 0.86
Insider Trans -0.84%
Shs Float 25.57M
Perf Month -14.48%
Income -64.30M
PEG -
EPS next Q -0.45
Inst Own 81.37%
Short Float 2.21%
Perf Quarter -34.26%
Sales 2.82B
P/S 0.17
EPS this Y -332.94%
Inst Trans -4.02%
Short Ratio 2.28
Perf Half Y -27.33%
Book/sh 30.18
P/B 0.57
EPS next Y 143.43%
ROA -3.63%
Short Interest 0.56M
Perf Year -40.27%
Cash/sh 0.48
P/C 35.72
EPS next 5Y 10.00%
ROE -7.23%
52W Range 16.90 - 36.64
Perf YTD -42.61%
Dividend Est. 0.75 (4.33%)
P/FCF -
EPS past 5Y -
ROI -4.91%
52W High -52.76%
Beta 1.64
Dividend TTM 0.75 (4.33%)
Quick Ratio 0.92
Sales past 5Y 8.12%
Gross Margin 9.41%
52W Low 2.43%
ATR (14) 0.91
Dividend Ex-Date Apr 19, 2024
Current Ratio 1.96
EPS Y/Y TTM -189.47%
Oper. Margin 0.43%
RSI (14) 37.93
Volatility 4.13% 5.29%
Employees 3353
Debt/Eq 0.58
Sales Y/Y TTM -13.43%
Profit Margin -2.28%
Recom 4.00
Target Price 17.00
Option/Short Yes / Yes
LT Debt/Eq 0.55
EPS Q/Q -885.14%
Payout -
Rel Volume 1.23
Prev Close 17.42
Sales Surprise -0.84%
EPS Surprise 5.02%
Sales Q/Q -17.84%
Earnings Apr 04 BMO
Avg Volume 247.79K
Price 17.31
SMA20 -6.51%
SMA50 -12.01%
SMA200 -33.27%
Trades
Volume 304,886
Change -0.63%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-28-24 Downgrade
Seaport Research Partners
Neutral → Sell
$17.50
Dec-14-23 Initiated
Seaport Research Partners
Neutral
May-19-22 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Mar-24-22 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$58
Jul-19-21 Initiated
Northland Capital
Outperform
$80
Apr-09-21 Initiated
Goldman
Buy
$48
Jan-12-21 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Nov-20-20 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$28
Oct-10-19 Reiterated
Cowen
Market Perform
$22 → $21
Sep-23-19 Downgrade
Goldman
Neutral → Sell
$27 → $23
Jun-25-19 Reiterated
Cowen
Market Perform
$24 → $25
Jan-14-19 Downgrade
Goldman
Buy → Neutral
Jan-09-19 Initiated
Cowen
Market Perform
$24
Aug-15-18 Downgrade
Morgan Stanley
Equal-Weight → Underweight
Mar-20-18 Initiated
Goldman
Buy
$42
Sep-07-17 Initiated
Macquarie
Neutral
Apr-01-16 Reiterated
DA Davidson
Neutral
$15 → $18
Nov-24-15 Upgrade
Morgan Stanley
Underweight → Equal-Weight
Jul-01-15 Upgrade
BofA/Merrill
Underperform → Buy
Jan-05-15 Downgrade
DA Davidson
Buy → Neutral
$34 → $25
Show Previous Ratings
Apr-16-24 09:00AM
Apr-08-24 09:10AM
Apr-05-24 05:48PM
Apr-04-24 09:31AM
08:00AM
10:58AM
Loading…
Mar-18-24 10:58AM
Mar-14-24 04:35PM
Mar-09-24 07:48AM
Mar-04-24 08:30AM
Jan-06-24 08:07AM
Jan-05-24 01:20AM
(Thomson Reuters StreetEvents)
Jan-04-24 03:06PM
08:17AM
(Associated Press Finance)
08:00AM
Dec-18-23 09:00AM
09:15AM
Loading…
Dec-13-23 09:15AM
Nov-16-23 08:30AM
Oct-26-23 10:01AM
01:25AM
(Thomson Reuters StreetEvents)
Oct-25-23 09:43AM
08:26AM
(Associated Press Finance)
08:00AM
Sep-29-23 08:30AM
Aug-30-23 08:00AM
Aug-10-23 05:31PM
(American City Business Journals)
Jul-26-23 05:45PM
(American City Business Journals)
04:00PM
Jul-04-23 07:33AM
Jun-30-23 12:48PM
06:12AM
07:29AM
Loading…
Jun-29-23 07:29AM
(Investor's Business Daily)
Jun-28-23 04:43PM
(Investor's Business Daily)
04:13PM
(Investor's Business Daily)
03:30PM
(Investor's Business Daily)
02:18AM
(Thomson Reuters StreetEvents)
Jun-27-23 04:09PM
(Investor's Business Daily)
08:13AM
08:00AM
Jun-26-23 04:07PM
(Investor's Business Daily)
Jun-23-23 06:46PM
(Investor's Business Daily)
03:01PM
(Investor's Business Daily)
Jun-21-23 08:45AM
Jun-18-23 10:02AM
Jun-12-23 08:30AM
Jun-03-23 09:01AM
May-19-23 09:20AM
May-05-23 08:41AM
Apr-14-23 09:30AM
Apr-10-23 08:45AM
Apr-08-23 08:20AM
Apr-07-23 12:22AM
Apr-05-23 08:21AM
08:00AM
Mar-28-23 09:40AM
Mar-20-23 06:00PM
05:00PM
Mar-16-23 08:34AM
Mar-13-23 07:00AM
Mar-10-23 06:00PM
Feb-28-23 06:00PM
Feb-22-23 06:00PM
Feb-14-23 06:00PM
Jan-30-23 02:38PM
Jan-22-23 07:19AM
Jan-18-23 07:30AM
01:03AM
Jan-10-23 06:50AM
Jan-09-23 07:18AM
Jan-08-23 07:17AM
Jan-05-23 08:00AM
Jan-03-23 09:40AM
Jan-02-23 05:53AM
Dec-29-22 10:00AM
Dec-26-22 09:40AM
Dec-19-22 04:30PM
Dec-16-22 07:29AM
Dec-15-22 08:30AM
Dec-12-22 10:24AM
Nov-25-22 01:42PM
Nov-16-22 10:25AM
Nov-14-22 08:30AM
Nov-05-22 08:19AM
Oct-27-22 06:41AM
Oct-24-22 08:00AM
Oct-20-22 10:02AM
Oct-17-22 10:00AM
Oct-12-22 09:00AM
08:26AM
Oct-07-22 07:58AM
Oct-04-22 06:30PM
Aug-01-22 06:17PM
(American City Business Journals)
08:30AM
Jul-20-22 08:56AM
Jul-07-22 08:54AM
Jul-02-22 08:18AM
Jun-29-22 10:01AM
09:15AM
08:00AM
Jun-24-22 09:33AM
Jun-14-22 03:32PM
Radius Recycling, Inc. engages in the recycling of ferrous and nonferrous scrap metal and manufacture of finished steel products. The company was founded by Sam Schnitzer in 1906 and is headquartered in Portland, OR.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Souza Brian SVP, Chief Ops Mgmt Officer Nov 10 '23 Sale 23.49 4,500 105,705 18,767 Nov 14 07:13 PM Heiskell Steven SVP & President, Recycling P&S Nov 07 '23 Sale 24.14 8,000 193,120 136,367 Nov 08 06:50 PM Vaughn James Matthew SVP, GC, CCO, Corp. Secretary Nov 06 '23 Sale 24.83 571 14,178 6,608 Nov 07 01:42 PM Gaggini Stefano R. SVP, CFO Nov 03 '23 Sale 24.86 7,269 180,707 63,295 Nov 07 01:35 PM Heiskell Steven SVP, Products & Services May 05 '23 Sale 28.64 1,649 47,227 131,523 May 09 12:17 PM Henderson Michael R SVP, President, Operations May 04 '23 Sale 27.44 1,691 46,401 132,769 May 08 10:28 AM Gaggini Stefano R. SVP, CFO May 03 '23 Sale 28.43 1,026 29,164 62,374 May 05 12:15 PM Schuessler Mark VP and CAO May 03 '23 Sale 28.51 157 4,476 7,730 May 05 12:16 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite